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The clonogenic growth of advanced breast tumour lesions adds no value to
that of established clinical prognosticators for survival
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Summary We measured the clonogenic growth of 110 breast cancer samples obtained from 107 patients with
advanced disease. We determined clonogenicity under conventional conditions and under conditions supple-
mented with growthfactors and hormones that target breast tissue. After a median follow-up period of 6 years
we analysed our data to determine if and to what degree clonogenic growth of metastatic breast tumours was
related to the survival of patients. We found that tumour clonogenicity and patient survival correlated weakly,
particularly if compared to the strong correlations of patient survival with either performance status or
tumour bulk. Furthermore, an association between tumour clonogenicity and patient survival was visible only
for clonogenicity that was determined under hormone-supplemented conditions, and only for tumour lesions
that formed 50 or more colonies per 500,000 cells cultured. Thus, we conclude that clonogenic growth of
breast tumour samples incompletely reflects the tumour features that determine the course ofadvanced disease.
Advanced breast carcinoma is with few exceptions a fatal
disease. Tumours kill their host either by accumulating a
load whose metabolic burden is incompatible with life or by
destroying vital tissue organs or by paralysing host reactivity.
In the first mode of killing the tumour acts through its ability
to proliferate; in the other two modes the tumour acts
through its ability to metastasise and to destroy the micro-
environment. Prognostic factors that predict the length of
survival of patients with advanced breast carcinoma are the
performance status of patients, the number of organ sites
involved with metastatic tumour, and the efficacy of treat-
ment in arresting tumour progression. Thus, among those
factors that determine the prognosis of patients, treatment is
the only factor that can be modified.
While different characteristics of tumour cells may mediate
the lethal event, treatment is generally directed at interfering
with the ability of tumour cells to proliferate. Further to this
aim, the clonogenic assay has been used as a tool to measure
the intrinsic chemosensitivities of proliferating tumour stem
cells (Von-Hoff et al., 1981a, 1981b, 1983, 1986; Ruckdeschel
et al., 1987; Brock et al., 1989; Huot et al., 1990). However,
the value of the assay in attempts to alter the disease course
remains uncertain (Smallwood et al., 1984; Trotter et al.,
1984; Nomura et al., 1989).
The other characteristics of tumour cells that may also
lead to a final lethal event are rarely, if ever, considered in
the design of new treatments. Yet there is evidence that the
tumours' interaction with its host can be lethal by means of
its metastatic properties or by means of its host-suppressive
property (Briozzo et al., 1988; Pourreau-Schneider et al.,
1989). Since only treatment can modulate the survival of
these patients, it is important to know precisely if and how
treatment affects each of these tumour cell characteristics:
metastatic vs host-suppressive vs proliferative.
We have attempted to delineate, in patients with advanced
breast carcinoma, the impact on disease outcome of tumour
proliferative ability. To do so, we determined the predictive
value of the clonogenicity of local and distant tumour lesions
on the survival of patients, using clonogenicity as a measure
of proliferation. We compared the prognostic value of
tumour clonogenicity to the prognostic value of performance
status and to that of tumour extent, alone and in combina-
tion. Here we report our findings.
Methods
Patients
From 1981 through 1983, 110 patients with breast carcinoma
were studied for tumour clonogenicity, performance status,
and extent of disease. All patients had biopsiable or aspirable
tumours and were treated in the Breast Section of the
Department of Medical Oncology, The University of Texas
M.D. Anderson Cancer Center. Twenty-five patients had
locoregional advanced breast carcinoma (T4,N1-3,MO), and
85 patients had distant metastatic disease (TI-3,N1-3,M1).
Patients were staged according to the criteria set by the
International Union against Cancer and the American Joint
Committee for Cancer Staging and End-Results Reporting.
All patients had received hormone therapy, chemotherapy, or
both before their tumours were assayed for clonogenicity.
Follow-up
Following the clonogenic assay, most patients received one
or several regimens of chemotherapy, hormone therapy, or
both. Some patients received only supportive treatments. The
results of the in vitro chemosensitivity tests were not used for
treatment selection. All patients were followed at regular
intervals, as necessary for their management, to the time of
analysis or to death. For patients who died outside of the
institution, date of death was obtained by the Department of
Patient Studies.
Tumours
One hundred and thirteen primary or metastatic tumour
samples were obtained. Twenty-five specimens were obtained
at the time of debulking mastectomy, 42 specimens during
the course of diagnostic surgical biopsy, and the remaining
by aspiration of malignant effusions.
Specimens were collected into 20 ml of growth medium
admixed with 15% foetal bovine serum (KC Biological,
Lenexa, KS). Single-cell suspensions were prepared and cul-
tured, and cultures scored as previously described (Hug et al.,
1984). For hormone-supplemented conditions, 5 x 10-7 M
17-beta-estradiol, 10 microgram ml-' insulin, 2.5 microgram
ml-' hydrocortisone, and 50 ng ml-' epidermal growth factor
were added to both culture layers. Viability of single-cell
suspensions was determined by the trypan blue exclusion
method; percentage of tumour cells by enumerating the pro-
portion of cells with a diameter > = 10 micrometer under
40 x magnification.
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Statistical methods
Comparisons of patient survival with clonogenicity of their
tumours (determined under two different culture conditions)
were performed after a medium follow-up period of 6 years
(range, 4-8 years). Patient survival was also compared to
performance status at the time of sample collection and to
number of organ sites involved with tumour. Univariate and
multivariate analyses were used for these comparisons of
prognostic factors. The student's t-test was used for com-
parisons of distribution of tumour samples and patient sub-
sets.
1.0 -
0.8-
0.6-
0.4-
Results
The characteristics of patients were as follows: 107 patients
could be evaluated. One patient was lost to follow-up, and
the cultures of two patients were contaminated with bacterial
overgrowth. The median performance status of patients
(using the Zubrod scale) was one and ranged from 0-4. The
median number of organ sites involved with tumour was two
and ranged from 1-5. Twenty-seven patients had received
one prior chemotherapy treatment: 25 preoperatively to
reduce the tumour to operable size, two as first treatment for
distant disease. All others had received two or more prior
chemotherapy treatments.
The median survival of patients was 12 months. The two
conventional prognostic factors for survival, i.e. performance
status (estimated by the Zubrod scale) and disease extent
(estimated by the number of organ sites involved with
tumour metastases) separated our patients into groups of
distinctive prognosis (Figure la and b). The two conventional
prognostic factors in combination, expressed as 'predictive
score' (Table I), separated the patients even more distinctly
into groups of different survival.
The characteristics of in vitro tumour growth were as
follows: 110 tumour cultures could be evaluated. Under con-
ventional conditions, tumours formed a median number of
60 colonies per 500,000 cells seeded; under hormone-enriched
conditions, tumours formed a median number of 204 colon-
ies. The number of colonies ranged from 0 to 656 under
conventional conditions and from 1 to 2062 under hormone-
supplemented conditions. Forty-three samples were derived
from effusions, 67 samples from soft tissues. The median
viability of cell-suspensions was 88% (88% for fluids, and
87% for soft tissues). The median percentage of tumour cells
in suspensions was 64 (59 for fluids and 67 for soft tissues,
P<0.01).
Under hormone-supplemented conditions, locoregional
tumours formed 165 colonies in the average, and distant
metastatic tumours formed 237 colonies in the average. The
mean and median values of tumour clonogenicity obtained
from subsets ofpatients under hormone-supplemented condi-
tions are listed in Table II. In most instances the two values
were widely separated.
While performance status and disease extent separated the
investigated patients into groups with distinct survival dura-
tion, tumour clonogenicity did not. Only after patients with
low-clonogenic tumours were deleted from the multiregres-
sion analysis could an inverse relationship between clono-
genicity of tumours and survival of patients be observed.
This inverse correlation was, however, weak and not statis-
Table I Predictive power for survival of patients studied for
clonogenicity
Predictive No. of Survival
scorea observations (months) P-value"
1 36 40 > 10-2
2,3 37 17> 10-7
4-9 374
aNumber ofmetastatic organ sitesplusperformance statusaccording
to the Zubrod scale. bGeneralised Wilcoxon Test.
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Figure 1 a, Survival of patients with breast carcinoma in rela-
tion to performance status determined at the time of biopsy for
the clonogenic assay. *: performance status by the Zubrod
scale = 0; *: performance status = 1; 0: performance status = 2;
A: performance status = 3; X: performance status =4. b, Sur-
vival of patients in relation to number of organ sites involved
with metastatic tumour at the time of biopsy for the clonogenic
assay. M: 1 organ site involved; *: 2 organ sites involved; 0: 3,
4, or 5 organ sites involved.
tically significant; and even then it was observed only under
hormone-supplemented culture conditions (see Figure 2a),
not under conventional conditions (see Figure 2b). If, how-
ever, we separated groups by the 'predictive score' (Table I),
increasing clonogenicity under hormone-supplemented condi-
tions correlated with decreasing survival in two.
Surprisingly, patients with tumours of low clonogenicity
(<0.002% under conventional culture conditions and
<0.01% under hormone-supplemented conditions) had the
shortest survival. Patients with tumours of low clonogenicity
comprised 23% of all patients; and 25% of tumours evalu-
ated were low clonogenic.
We compared cell viability and percentage of tumour cells
contained in the single-cell suspensions among specimens that
yielded scant tumour growth and specimens that yielded
abundant tumour growth. We found that fewer viable
tumour cells had been set into the cultures that yielded scant
growth than were set into those cultures that yielded abun-224 V. HUG et al.
Table II In vitro growth under hormone-supplemented conditions in relation to tumour charac-
teristics
Colonies/500,000 cells
Characteristic No. ofobserv. Mean Median P-value
ER-content
ER>= 0fmolmg-' protein 31 139 80
ER<lO fmol mg ' protein 27 195 95 >0.05
Source
Effusions 43 277 122
Solid tumour lesions 67 158 105 0.03
Treatment exposure
1 prior treatment 27 204 204
> = 2 prior treatments 83 205 94 >0.05
Disease extent
Locoregional disease 50 165 94
Distant disease 60 237 125 >0.05
a dant growth. Thus, the mean viability was 77% for single-cell
1.0- Censored Uncensored suspensions that yielded scant growth and 91% for single-cell
* 7 21 suspensions that yielded abundant growth (P<0.005). Con-
* 8 19 versely, the percentage of tumour cells, whether viable or
a b n . 5 23 nonviable, had been similar in single-cell suspensions that
0.8- * 5 yielded scant and abundant growth (65% and 69%, respec-
tively).
Table III illustrates the distribution among scant and
0.6- lnLI iabundant growers for some of the tumour characteristics
0.6 L \listed in Table II that may also have affected tumour clono-
genicity. The mean 'predictive score' for patients with low
clonogenic tumours was 2.8. However, 56% of low clono-
0.4- genic tumours were derived from fluids, and the survival for
patients whose tumour cells were sampled from malignant
effusions was significantly shorter than that for patients
whose tumour cells were sampled from soft tissue lesions (14
0.2- vs 22 months respectively, P<0.005).
Discussion
c
0.0 In a group of 107 patients with advanced breast carcinoma
o I0 I0 30 I0 50 60 70 we could find no significant association between clonogenic
0 10 2'0 30 40 5'0 6'0 7'0 Cb tumour growth and survival of patients. Patients with non-
0 measurable (absent) or low tumour clonogenicity (<10-4
0 1.ol ;, Censored Uncensored colonies formed under hormone-supplemented conditions per
0 * 2 25 500,000 cells seeded) experienced a shorter survival than
L- dog* 9 18 patients with higher tumour clonogenicity. For patients with
0.8- * 8 20 higher tumour clonogenicity a weak inverse association of clonogenicity and survival of patients did exist, but this
inverse association could be observed only for clonogenicity
determined under hormone-supplemented culture conditions.
0.6- Similar inverse associations between tumour clonogenicity
and patient survival have been observed previously, for
patients with breast tumours and for patients with other solid
tumours (Giovanni et al., 1988). However, positive associa-
0.4- tions between tumour clonogenicity and patient survival have
also been described.
While supplementation of cultures with hormone that
0.2- target breast tissue also enhanced the clonogenic growth of tumours that had metastasised to distant organ tissues, scant
clonogenic growth was observed more commonly from
tumours that were sampled from malignant fluids (33%) than
0.0- from tumours that were sampled from soft tissues (16%).
. T_ , , , , , ,Although the average clonogenic growth of malignant effus-
o 10 20 30 40 50 60 70 ions was slightly higher than that of soft tissues, the clono-
Months genic growth of malignant effusions was more variable than
that of soft tissues.
2 a, Survival of patients with breast carcinoma in rela-
tumour clonogenicity determined under hormone-enriched Table III Distribution of tumour characteristics among samples
ons (see Methods section for details of conditions). *: growing <50 colonies and samour growing > =amonies
colonies formed ner 1 cells eeded- *- Al samples nies %IA11v1 AWAM4 FFvss9 av%P1su Y1 VvWv M;Uq.U 'SWs. lVI--J I
colonies formed per 500,000 cells seeded; 0: >237 colonies per
500,000 cells seeded. b, Survival ofpatients in relation to tumour
clonogenicity determined under regular conditions (see Methods
section for details). *: 10-38 colonies formed per 500,000 cells
seeded; *: 39-85 colonies formed per 500,000 cells seeded; 0:
>85 colonies per 500,000 cells seeded. P-value >0.5 for overall
distribution of curves.
Growth category
Tumour characteristics < 50colonies > = 50colonies
Number of samples 25 85
Derived from solid tumour lesions 11 (44%) 56 (66%)
ER> = 10fmol mg-I protein 6 (24%) 25 (29%)
Extended to only one metastatic site 10 (40%) 40 (47%)
Figure:
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There are also tumour-biological principles that may ex-
plain our inability to recover the most virulent tumour sub-
populations. As the disease progresses some tumour cell
clones will escape endocrine control, and paracrine factors,
such as matrix substances or secretory products from suppor-
tive stromal cells, may regulate tumour cell proliferation.
Thus, stromal cells release the cytokines necessary for tumour
cell adherence, invasion, and proliferation, while matrix ele-
ments transmit environmental growth signals to the nucleus.
That we failed to include these components in our culture
system may explain our inability to recovery all tumour cell
subpopulations. This would suggest that not only the ability
of tumour cells to proliferate, but also their ability to metas-
tasise and to suppress host reactivity, influences the disease
outcome.
An alternative explanation for our inability to recover the
biologically most relevant tumour subclones may be the pos-
sibility that in vivo tumour growth is primarily determined by
growth inhibitors (Arteaga et al., 1988), while in vitro tumour
growth is primarily determined by growth stimulatory sub-
stances (Yee et al., 1988; Osborne et al., 1989; Cormier et al.,
1989). Thus, using stimulators of growth could result in in
vitro tumour growth that has no bearing to the in vivo
tumour growth.
Regardless ofwhich explanation is closest to the truth, it is
safe to conclude that the proliferative ability of tumour cells,
measured by their clonogenicity under regular and under
hormone-enriched culture conditions, is not the only and
certainly not the most important feature of tumour cells that
controls the clinical course of the disease.
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